Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-FD4
- Development stage
- Preclinical
- Lead developer
- SynuSight Biotech
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals
- Administration
- Intravenous
01
Overview
18F-FD4 is a radiopharmaceutical tracer labeled with Fluorine-18 (18F) developed for use in Positron Emission Tomography (PET) imaging. Its primary application is to detect and visualize alpha-synuclein aggregates in the brain, a key pathological hallmark of neurodegenerative disorders such as Parkinson's disease and multiple system atrophy. The tracer is administered via injection and is currently being investigated in clinical studies by institutions including Huashan Hospital, Fudan University, and the National Natural Science Foundation of China.
02
Targets
α-syn fibril (Alpha-synuclein (SNCA))
Beyond the preview
Go deeper on 18F-FD4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-FD4.